Comparison of the Clinical Validity of Free Prostate&amp;ndash;Specific Antigen, Alpha&amp;ndash;1 Antichymotrypsin&amp;ndash;Bound Prostate&amp;ndash;Specific Antigen and Complexed Prostate&amp;ndash;Specific Antigen in Prostate Cancer Diagnosis

Lein, Michael; Jung, Klaus; Elgeti, Ulrike; Petras, Tobias; Stephan, Carsten; Brux, Brigitte; Sinha, Pranav; Winkelmann, Bj&ouml;rn; Schnorr, Dietmar; Loening, Stefan A.

doi:10.1159/000052413

Cited by 20 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some workers have compared the ratio of free to total PSA or free to complexed PSA. [3,4] Others have used plasma lipid levels, [5,6] vitamin E (α and γ tocopherol), [7] trace metal-Selenium, [8] and serum to urinary PSA ratio. [9,10] These previous studies have produced varying outcomes with merits and shortcomings.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer

Adedapo

Arinola

et al. 2012

Niger J Clin Pract

View full text Add to dashboard Cite

Prior to prostate biopsy, serum lipid (especially, fasting triglycerides, total cholesterol) could help in early discrimination of patients with BPH from prostate cancer in adjunct to total PSA and other management protocol for diagnosis of prostate cancer. The use of trace metal or antioxidants may have limited advantages. Further studies in this regard will be very desirable to see if this pattern of triglyceride and total cholesterol values in BPH and Pca are sustainable.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer

Adedapo

Arinola

et al. 2012

Niger J Clin Pract

View full text Add to dashboard Cite

show abstract

“…The test is a two-step sandwich assay based on the biotin-streptavidin technology and uses a peroxidase-labeled antibody specific against PSA-ACT. 20 The analytical characteristics of these assays (precision, detection limit, recovery, interferences) corresponded to data previously described in detail. 20,22 During this study, the inter-assay precisions for all assays were controlled with control materials in the low PSA range (tPSA: 0.79, 2.70, 3.34 g/l; cPSA: 3.31 g/l; PSA-ACT: 2.51 g/l; fPSA: 0.99 g/l) and showed variation coefficients between 1.8 and 4.5%.…”

Section: Determination Of Psamentioning

confidence: 67%

“…19 A novel PSA assay introduced by Bayer that measures all the complexed PSA (cPSA) except PSA complexed with ␣ 2 -macroglobulin and a prototype PSA-ACT assay have eliminated the technical obstacles to reliable measurement of these PSA forms. 18,20 These new assays for determining complexed PSA forms and the assay for fPSA were used in this study to gain further insights Abbreviations: ACT, ␣ 1 -antichymotrypsin; BPH, benign prostatic hyperplasia; cPSA, complexed form of PSA; fPSA, free, noncomplexed form of PSA; PCa, prostate cancer; PSA, prostate-specific antigen; ROC, receiver operating characteristic; tPSA, total PSA, both free and complexed forms.…”

mentioning

confidence: 99%

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?

et al. 2001

Self Cite

View full text Add to dashboard Cite

Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 g/l. To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identification of men with PCa in the low PSA range of <4 g/l, total PSA (tPSA), ␣ 1 -antichymotrypsin complexed PSA (PSA-ACT) and fPSA (Roche Elecsys [ES] system) as well as tPSA and complexed PSA (cPSA) (Bayer Immuno 1 system) were measured in archival serum samples from 31 untreated patients with PCa, 66 patients with BPH, and 90 men without prostatic disease. The median ratios of fPSA/tPSA, PSA-ACT/tPSA and cPSA/tPSA were significantly different between patients with BPH and PCa (27.2 vs. 19.4%, 64 vs. 88%, 77.2 vs. 88.2%, p < 0.05). No associations between PSA forms and tumor stage and grade were found. Analysis of the receiver operating characteristic curves showed that these ratios could discriminate better between BPH and PCa patients than determination of the analytes tPSA, fPSA, cPSA and PSA-ACT alone. The use of one of the ratios would have eliminated roughly half of the unnecessary biopsies in this study. The ratios should be considered as potential tools to increase the selectivity of PCa detection at low PSA concentration. The ratios fPSA/tPSA and cPSA/tPSA can be determined using commercially available assays so that one of these ratios could be preferred instead of PSA-ACT determination. The ratios could be useful in assessing the risk of PCa in the individual and therefore in deciding on prostate biopsy for final diagnosis.

show abstract

“…16,17 However, other studies using more equal tPSA distributions in patients with BPH and prostate cancer could only show a slightly better diagnostic performance of cPSA alone compared with tPSA. 36,38,39 Only the cPSA/tPSA ratio could reach specificity levels comparable to %fPSA. 18,40 The preliminary data of a cPSA multicenter study has revealed a better performance of the cPSA/tPSA ratio in the 4 to 10 ng/mL tPSA range compared with cPSA alone, but in the lower range of 2 to 6 ng/mL, cPSA outperformed the cPSA/tPSA ratio.…”

Section: Psa-act and Cpsamentioning

confidence: 97%

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Stephan

Jung

Diamandis

et al. 2002

Urology

Self Cite

View full text Add to dashboard Cite

Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis

Cited by 20 publications

References 29 publications

Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer

Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Contact Info

Product

Resources

About